Please login to the form below

Not currently logged in
Email:
Password:
PMLiVE Top Pharma List

Tarceva

The Top Pharma List's top 50 pharmaceutical products by global sales ranking is compiled from GlobalData's pharmaceutical revenue figures. Tarceva was produced by Roche and Astellas.

FDA approval gained, Pfizer sets sights on first-line NSCLC market

FDA approval gained, Pfizer sets sights on first-line NSCLC market

The second-generation EGFR tyrosine kinase inhibitor has been shown in trials to be more effective that first-generation drugs such as AstraZeneca’s Iressa (gefitinib) and Roche’s Tarceva (erlotinib) ... Approval now gained based on that data,

AZ’s soon-to-be lung cancer blockbuster Tagrisso approved in Japan

AZ’s soon-to-be lung cancer blockbuster Tagrisso approved in Japan The drug was also reviewed against other first-line EGFR tyrosine kinase inhibitors – Roche’s Tarceva and AZ’s and Teva’s Iressa – in previously untreated patients with locally-advanced or

Daiichi gets breakthrough status for pre-NDA leukaemia drug

Daiichi gets breakthrough status for pre-NDA leukaemia drug of HER3 inhibitor patritumab in combination with Roche’s EGFR drug Tarceva (erlotinib) in the same indication on disappointing efficacy data.

Daily Brief: Tagrisso's first line approval, EULAR and EHA, and why Stephen Hawking was wrong on NHS

Daily Brief: Tagrisso's first line approval, EULAR and EHA, and why Stephen Hawking was wrong on NHS head-to-head with existing EGFR drugs, Roche’s Tarceva and AstraZeneca’s own Iressa.

CHMP backs first-line use for AZ’s Tagrisso in lung cancer

CHMP backs first-line use for AZ’s Tagrisso in lung cancer comparator EGFR inhibitors including Roche’s Tarceva (erlotinib) or AZ’s earlier-generation EGFR drug Iressa (gefitinib).

1 2 3 4 5 6 7 8 9 10 [ Next 5 results ]

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Complete Medical Communications (CMC)

CMC is a leading global agency dedicated to healthcare communications across the lifecycle. We combine scientific acumen, excellence in delivery...

Latest intelligence

The UK’s new five-year pricing agreement
Pharma has agreed to capped growth again - in exchange for uptake promises...
Digital applications are transforming the market access landscape
Organisations are leveraging new technology to implement a wider range of business models and, in essence, drive market access success by working smarter, faster and with greater economy....
Escaping the spin cycle of sub-optimal launch
...

Infographics